Merck acquires rights to potential Ebola vaccine in $50M deal
Philadelphia Business Journal
By John George
Merck & Co Inc. entered into a deal for an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink Genetics Corp.'s investigational Ebola vaccine candidate.
Under the terms of the deal, New Link Genetics of Ames, Iowa, will receive $50 million plus royalties from Merck. Merck gets rights to the vaccine candidate and any follow-on products.
Click here to read the full story.